BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38600356)

  • 21. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
    Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
    Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.
    Ponzetta A; Benigni G; Antonangeli F; Sciumè G; Sanseviero E; Zingoni A; Ricciardi MR; Petrucci MT; Santoni A; Bernardini G
    Cancer Res; 2015 Nov; 75(22):4766-77. PubMed ID: 26438594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression.
    Kline M; Donovan K; Wellik L; Lust C; Jin W; Moon-Tasson L; Xiong Y; Witzig TE; Kumar S; Rajkumar SV; Lust JA
    Leuk Res; 2007 May; 31(5):591-8. PubMed ID: 16879867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
    Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
    Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
    Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.
    Chatterjee M; Hönemann D; Lentzsch S; Bommert K; Sers C; Herrmann P; Mathas S; Dörken B; Bargou RC
    Blood; 2002 Nov; 100(9):3311-8. PubMed ID: 12384432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.
    Tamura H; Ishibashi M; Yamashita T; Tanosaki S; Okuyama N; Kondo A; Hyodo H; Shinya E; Takahashi H; Dong H; Tamada K; Chen L; Dan K; Ogata K
    Leukemia; 2013 Feb; 27(2):464-72. PubMed ID: 22828443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.
    Pitari MR; Rossi M; Amodio N; Botta C; Morelli E; Federico C; Gullà A; Caracciolo D; Di Martino MT; Arbitrio M; Giordano A; Tagliaferri P; Tassone P
    Oncotarget; 2015 Sep; 6(29):27343-58. PubMed ID: 26160841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
    Bar-Natan M; Stroopinsky D; Luptakova K; Coll MD; Apel A; Rajabi H; Pyzer AR; Palmer K; Reagan MR; Nahas MR; Karp Leaf R; Jain S; Arnason J; Ghobrial IM; Anderson KC; Kufe D; Rosenblatt J; Avigan D
    Br J Haematol; 2017 Mar; 176(6):929-938. PubMed ID: 28107546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.
    Michigami T; Shimizu N; Williams PJ; Niewolna M; Dallas SL; Mundy GR; Yoneda T
    Blood; 2000 Sep; 96(5):1953-60. PubMed ID: 10961900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
    Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
    Fowler JA; Mundy GR; Lwin ST; Edwards CM
    Cancer Res; 2012 May; 72(9):2183-9. PubMed ID: 22374979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche.
    Raffaghello L; Bianchi G; Bertolotto M; Montecucco F; Busca A; Dallegri F; Ottonello L; Pistoia V
    Stem Cells; 2008 Jan; 26(1):151-62. PubMed ID: 17932421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.
    Wallace SR; Oken MM; Lunetta KL; Panoskaltsis-Mortari A; Masellis AM
    Cancer; 2001 Apr; 91(7):1219-30. PubMed ID: 11283920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma.
    Faid L; Van Riet I; De Waele M; Facon T; Schots R; Lacor P; Van Camp B
    Eur J Haematol; 1996 Nov; 57(5):349-58. PubMed ID: 9003475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells.
    Chatterjee M; Stühmer T; Herrmann P; Bommert K; Dörken B; Bargou RC
    Blood; 2004 Dec; 104(12):3712-21. PubMed ID: 15297310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF.
    He C; Zhang M; Liu L; Han Y; Xu Z; Xiong Y; Yan F; Su D; Chen H; Zheng Y; Cheng F
    Acta Biomater; 2022 Apr; 143():406-417. PubMed ID: 35218967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
    Dankbar B; Padró T; Leo R; Feldmann B; Kropff M; Mesters RM; Serve H; Berdel WE; Kienast J
    Blood; 2000 Apr; 95(8):2630-6. PubMed ID: 10753844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.
    Hiruma Y; Honjo T; Jelinek DF; Windle JJ; Shin J; Roodman GD; Kurihara N
    Blood; 2009 May; 113(20):4894-902. PubMed ID: 19282458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.